312.58
2.27 (0.73%)
| Previous Close | 310.31 |
| Open | 309.53 |
| Volume | 311,309 |
| Avg. Volume (3M) | 303,651 |
| Market Cap | 9,214,781,440 |
| Price / Earnings (TTM) | 41.51 |
| Price / Earnings (Forward) | 49.75 |
| Price / Sales | 20.70 |
| Price / Book | 6.63 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2026 |
| Profit Margin | 37.17% |
| Operating Margin (TTM) | 41.03% |
| Diluted EPS (TTM) | 4.18 |
| Quarterly Revenue Growth (YOY) | 94.90% |
| Quarterly Earnings Growth (YOY) | 3,734.00% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 9.65 |
| Operating Cash Flow (TTM) | 138.50 M |
| Levered Free Cash Flow (TTM) | 76.74 M |
| Return on Assets (TTM) | 8.66% |
| Return on Equity (TTM) | 13.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Krystal Biotech, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.88% |
| % Held by Institutions | 104.04% |
| 52 Weeks Range | ||
| Median | 284.00 (-9.14%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 25 Feb 2026 | 284.00 (-9.14%) | Buy | 272.50 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |